EN9 Stock Overview
A life science company, develops and sells products that treat and alleviate infections and symptoms in the upper respiratory tract. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Community vs My Fair Value
Create NarrativeSelect a narrative for quick price alerts from the community, or create your own.
Enzymatica AB (publ) Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | SEK 0.24 |
| 52 Week High | SEK 0.42 |
| 52 Week Low | SEK 0.089 |
| Beta | 0.39 |
| 1 Month Change | -30.38% |
| 3 Month Change | 117.51% |
| 1 Year Change | -4.06% |
| 3 Year Change | -46.24% |
| 5 Year Change | n/a |
| Change since IPO | -86.12% |
Recent News & Updates
Recent updates
Shareholder Returns
| EN9 | DE Pharmaceuticals | DE Market | |
|---|---|---|---|
| 7D | -17.8% | 2.2% | 2.5% |
| 1Y | -4.1% | -16.4% | 14.4% |
Return vs Industry: EN9 exceeded the German Pharmaceuticals industry which returned -16.4% over the past year.
Return vs Market: EN9 underperformed the German Market which returned 14.9% over the past year.
Price Volatility
| EN9 volatility | |
|---|---|
| EN9 Average Weekly Movement | 40.1% |
| Pharmaceuticals Industry Average Movement | 5.0% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in DE Market | 12.8% |
| 10% least volatile stocks in DE Market | 3.1% |
Stable Share Price: EN9's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: EN9's weekly volatility has increased from 24% to 40% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2007 | 21 | Claus Egstrand | www.enzymatica.se |
Enzymatica AB (publ), a life science company, develops and sells products that treat and alleviate infections and symptoms in the upper respiratory tract. The company’s product includes ColdZyme, a mouth spray to treat and alleviate cold and flu symptoms. It also provides enzyme formulations for skin care.
Enzymatica AB (publ) Fundamentals Summary
| EN9 fundamental statistics | |
|---|---|
| Market cap | €68.92m |
| Earnings (TTM) | -€4.79m |
| Revenue (TTM) | €4.44m |
15.5x
P/S Ratio-14.4x
P/E RatioIs EN9 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| EN9 income statement (TTM) | |
|---|---|
| Revenue | SEK 48.43m |
| Cost of Revenue | SEK 15.70m |
| Gross Profit | SEK 32.74m |
| Other Expenses | SEK 85.06m |
| Earnings | -SEK 52.32m |
Last Reported Earnings
Mar 31, 2025
Next Earnings Date
Jul 17, 2025
| Earnings per share (EPS) | -0.22 |
| Gross Margin | 67.59% |
| Net Profit Margin | -108.03% |
| Debt/Equity Ratio | 1.2% |
How did EN9 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/05/05 08:18 |
| End of Day Share Price | 2025/05/02 00:00 |
| Earnings | 2025/03/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Enzymatica AB (publ) is covered by 4 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Jakob Lembke | ABG Sundal Collier Sponsored |
| Peter Sellei | Penser Access |
| Maria Karlsson Osipova | Penser Access |